Symyx Technologies Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Symyx Technologies Inc.
Shire addresses its Replagal disappointment with the acquisition of FerroKin and its hematology pipeline.
Merck announced March 15 that it plans to invest $90 million over the next seven years in a nonprofit biomedical research center in San Diego dubbed the California Institute for Biomedical Research, or Calibr.
It was always a question of when, not if. Amgen needed to do something to provide for its post-EPO future; now the action has started. The big biotech went on a $720 million cash shopping spree in the early part of June, buying first Ilypsa Inc. for $420 million, then swallowing up Alantos Pharmaceuticals for $300 million a couple of days later.
Polymers have long been useful as critical components in delivering or stabilizing a variety of medicines. Now a small band of companies that includes Genzyme, Ilypsa and Midway Pharmaceuticals is going one step further: they are designing polymers that aren't just inert drug delivery vehicles, but are themselves therapeutic agents.
- Research, Analytical Equipment & Supplies
- Other Names / Subsidiaries
- Accelrys, Inc
- AG (Switzerland)
- Symyx Discovery Tools, Inc.
- Symyx Technologies International, Inc.
- Symyx IntelliChem, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.